Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development
Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Call Participants Kyle Boucher - TD Cowen Matt Stanton - Jefferies Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.
29 Jul 2025 (53 Days) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
29 Jul 2025 (53 Days) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Diagnostics & Research Industry | Healthcare Sector | Dr. Michael Egholm Ph.D. CEO | NASDAQ (NGS) Exchange | 34385P108 Cusip |
US Country | 814 Employees | - Last Dividend | - Last Split | 29 Jul 2003 IPO Date |
Standard BioTools Inc., previously known as Fluidigm Corporation until its name change in April 2022, is a significant player in providing comprehensive solutions for researchers and diagnostics labs across the globe. With its subsidiaries, it caters to a wide range of needs in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific regions. The company's operations are divided into two main segments: Proteomics and Genomics, offering a diverse range of advanced systems, consumables, reagents, and software services. Standard BioTools Inc. prides itself on enhancing research capacities in various fields such as academic institutions, clinical research laboratories, cancer centers, as well as biopharmaceutical and biotechnology companies, through its innovative product lineup. It leverages powerful license agreements with renowned institutions like the California Institute of Technology and Harvard University, underlining its commitment to cutting-edge research and technology.
Standard BioTools Inc. provides a robust suite of analytical systems, genomics solutions, and comprehensive services aimed at transforming research and clinical diagnostics. Key offerings include: